key: cord-0880388-sbw0e2ab authors: Pal, Rimesh; Singh, Birgurman; Bhadada, Sanjay Kumar; Banerjee, Mainak; Bhogal, Ranjitpal Singh; Hage, Neemu; Kumar, Ashok title: COVID‐19‐associated mucormycosis: An updated systematic review of literature date: 2021-06-25 journal: Mycoses DOI: 10.1111/myc.13338 sha: 2b1ffe5873b1e03daba538a555c33a74374d6508 doc_id: 880388 cord_uid: sbw0e2ab In its wake, the COVID‐19 pandemic has ushered in a surge in the number of cases of mucormycosis. Most cases are temporally linked to COVID‐19; hence, the entity is described as COVID‐19‐associated mucormycosis (CAM). The present systematic review was undertaken to provide an up‐to‐date summary of the hitherto available literature on CAM. PubMed, Scopus and Google Scholar databases were systematically searched using appropriate keywords till 14 May 2021, to identify case reports/case series pertaining to mucormycosis in patients with COVID‐19. Relevant data extracted included demographic characteristics, comorbidity profile, clinical category of mucormycosis, glucocorticoid use, treatment offered and patient outcome. We identified 30 case reports/case series, pooling data retrieved from 99 patients with CAM. Most cases were reported from India (72%). The majority of the patients was male (78%) and had diabetes mellitus (85%). A prior history of COVID‐19 was present in 37% patients with mucormycosis developing after an initial recovery. The median time interval between COVID‐19 diagnosis and the first evidence of mucormycosis infection or CAM diagnosis was 15 days. Glucocorticoid use was reported in 85% of cases. Rhino‐orbital mucormycosis was most common (42%), followed by rhino‐orbito‐cerebral mucormycosis (24%). Pulmonary mucormycosis was observed in 10 patients (10%). The mortality rate was 34%; the use of adjunct surgery, which was undertaken in 81% of patients, was associated with better clinical outcomes (p < .001). In conclusion, CAM is an emerging problem necessitating increased vigilance in COVID‐19 patients, even those who have recovered. CAM portends a poor prognosis and warrants early diagnosis and treatment. it had included only 43 cases. 9 Subsequently, there has been an upsurge in the number of cases of CAM that have been reported from all across the world. [10] [11] [12] [13] [14] [15] Hence, the present systematic review was undertaken to provide an up-to-date summary of the available literature on CAM. This systematic review was conducted and reported according to the Preferred Reporting Items for Systematic reviews and Metaanalyses (PRISMA) statement. 16 Eligibility criteria were set as follows: 1. Case reports and case series with a diagnosis of mucormycosis were included 2. Patients must have had a proven diagnosis of COVID-19 either prior to or at the time of development of mucormycosis 3. Patients having co-infections of mucormycosis and aspergillosis were also included Exclusion criteria were set as follows: 1. Patients having fungal infections other than mucormycosis were excluded 2. Patients without a confirmed diagnosis of COVID-19 (or serological evidence of prior COVID-19) were excluded 3. Reviews, systematic reviews, comments and editorials Two investigators (RP and MB) independently scanned titles and/or abstracts to exclude duplicate studies and studies that failed to meet the aforementioned eligibility criteria. Potentially eligible studies were full-text assessed. Any discrepancies between the aforementioned investigators were solved by discussion, consensus or arbitration by a third senior investigator (SKB). Studies hence selected were reviewed, and the following data were extracted from full-text reports for further assessment: study characteristics, number of patients reported, patient characteristics and comorbidities, present or prior history of COVID-19, the severity of COVID-19, the time from COVID-19 to mucormycosis diagnosis, presence or absence of diabetic ketoacidosis, the clinical category of mucormycosis, the fungal species isolated from clinical specimens, whether corticosteroids had been used for the management of COVID-19, use of other treatment modalities (like remdesivir, tocilizumab, convalescent plasma, antivirals and antibiotics), antifungal drug(s) used, any adjunct surgery performed for mucormycosis, investigations (blood glucose, C-reactive protein, ferritin, D-dimer and creatinine) and reported patient outcome (alive, deceased, or lost to follow-up). For the sake of uniformity, irrespective of the category assigned by the authors, wherever possible, we tried to classify the severity of COVID-19 as follows 17 : • Mild: Individuals who have any of the various signs and symptoms of COVID-19 but who do not have shortness of breath, dyspnoea or abnormal chest imaging • Moderate: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (SpO 2 ) ≥ 94% on room air at sea level • Severe: Individuals who have SpO 2 < 94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO 2 /FiO 2 ) < 300 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50% • Critical: Individuals who have respiratory failure, septic shock and/or multiple organ dysfunction Where the reported clinical data were insufficient, the disease severity designated by the authors was used for the present systematic review. We also tried to decipher the time interval between COVID-19 diagnosis and the onset of symptoms of mucormycosis. Mucormycosis was considered 'concurrent' if evidence of infection was present at the time of diagnosis of COVID-19. Reports where there was no clarity in the timing of onset of symptoms (as in patients with pulmonary mucormycosis complicating an underlying severe/critical COVID-19 disease), we considered the time when a diagnosis of mucormycosis was made. As all the included studies were either case reports or case series, a formal assessment of study quality and risk of bias was not performed. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) 23.0 software program (SPSS Inc, Chicago, IL, USA). Kolmogorov-Smirnov test was used to check the normality of the extracted data. Normally distributed data were expressed as mean ± standard deviation (SD), while nonparametric data were expressed in median (interquartile range, IQR). Categorical data were expressed as proportions (%). The comparison of demographic and other parameters between groups (alive vs. deceased) was made using independent samples t test (for continuous variables) or Pearson chi-square test/Fisher's exact test (for categorical variables). A p value <.05 was considered to be statistically significant. Following a thorough literature search and meticulous study selection process, we included 30 case reports/case series in our systematic review, pooling data retrieved from 99 patients with CAM. 1-8, [10] [11] [12] [13] [14] [15] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The study selection process has been summarised in the PRISMA flowchart ( Figure 1 ). The patient details extracted from the case reports/case series have been described in Tables S1 and S2. Out of these 30 studies, 21 were individual case reports , 1-7,10,11,18-27,29,31 while 9 were case series reporting 2, 12,28,32 6, 8, 15 10, 13,30 17 cases 33 and 23 cases, 14 respectively. Most of the cases were reported from India (71 cases, 72%) followed by the United States of America (10 cases, 10%), Egypt (6 cases, 6%), Iran (3 cases, 3%), Brazil (2 cases, 2%) and Chile (2 cases, 2%). One case each was reported from the United Kingdom, France, Italy, Austria and Mexico. Only 14 cases of CAM (14%) were reported in 2020, while the rest of the cases (86%) were reported in 2021. The analysed data have been summarised in Table 1 . Of note, there was a noticeable gender bias, with 78% of the cases being male. Diabetes mellitus was present in the majority of the cases (85%). Hypertension was the second most prevalent comorbidity after diabetes mellitus. Only four patients (4%) did not have any comorbidity. Most of the patients had a present history of COVID-19 (63%); nevertheless, the rest (37%) had a prior history of COVID-19 with mucormycosis developing after an initial recovery. Although COVID-19 was severe/critical in most patients (67%), mucormycosis developed even in patients with mild/moderate disease (24%). The median time interval between COVID-19 diagnosis and the first evidence of mucormycosis infection or CAM diagnosis was 15 days; however, mucormycosis developed even as late as 42 days and 90 days following COVID-19 diagnosis. 8, 26 The use of glucocorticoids for the management of COVID-19 was observed in 85% of the cases. Parenteral dexamethasone was the most commonly used glucocorticoid. The dose and duration of the glucocorticoid were infrequently reported across the included articles, hence, could not be analysed. Rhino-orbital mucormycosis was most common (42%), followed by rhino-orbito-cerebral mucormycosis (24%). Pulmonary mucormycosis was observed in 10 patients (10%). The predominant fungal organism identified was Rhizopus sp. Mixed mould infection (mucormycosis and aspergillosis) was reported in 4 patients. 10, 23, 32, 33 Surgery, as an adjunct to antifungal therapy, was undertaken in 81% of the patients. The biochemical parameters, namely HbA1c, blood glucose, CRP, ferritin, D-dimer and creatinine, were scarcely reported and excluded from the analysis. The final outcome was reported in 96 cases, while 3 patients were lost to follow-up. Out of these 96 cases, 33 (34%) were deceased, while 63 (66%) were alive. Table 2 depicts the differences in the clinical profile of patients who were alive compared to those who were deceased. Notably, patients with pulmonary mucormycosis showed a trend towards poor outcomes as compared to patients with rhino-orbital/rhino-cerebral/rhino-orbitocerebral mucormycosis (p = .084). Besides, the use of adjunct surgery was found to be associated with better clinical outcomes (p < .001). The present systematic review that had included 99 cases of CAM 15 Similarly, a prospective singlecentre observational study conducted in India from August 2020 to December 2020 identified 23 cases of invasive mucormycosis of the paranasal sinuses. 14 This is in stark contrast to a report published in 2015 from two large medical institutes in Mumbai, India that encompassed only 20 cases over a period of 3 years. 34 The majority of the cases have been temporally linked to COVID-19; hence, the entity is described as COVID-19-associated mucormycosis and abbreviated as CAM or CAMCR. 9, 29 Several observations have emerged from the present systematic review. We found a drastic geographical disparity, with most cases being reported from India (72%). Nevertheless, India has the highest TA B L E 1 Summarising the characteristics of the patients included in the systematic review Heart disease d 6 (12%) Obesity Asthma 2 (4%) Hypothyroidism Haematological malignancy 2 (4%) Obstructive sleep apnoea 1 (2%) burden of mucormycosis globally, with an estimated prevalence of 140 cases per million population. 35 Besides, India is home to nearly 77 million people with diabetes, with a nationwide prevalence of 7.3%. 36, 37 Diabetes mellitus being a major risk factor for mucormycosis, 35, [38] [39] [40] a spurt in the number of cases of CAM from India is not surprising. As would be expected, most of the patients had underlying diabetes mellitus (85%). Existing data suggest that individuals who lack phagocytes or have impaired phagocytic function are at higher risk of mucormycosis. 41 Apart from uncontrolled hyperglycemia, free unbound iron in serum plays an essential role in the pathogenesis of mucormycosis. Diabetic ketoacidosis, an important risk factor for mucormycosis, is associated with increased serum levels of free iron secondary to acidosis and proton-mediated displacement of ferric iron from transferrin. 50 Likewise, severe COVID-19 is a hyper-ferritinemic state. High serum ferritin leads to excess intracellular iron that generates reactive oxygen species and resultant death of hepatocytes. Cytokines, especially IL-6, stimulate ferritin synthesis and downregulate iron export resulting in intracellular iron overload, further aggravating the process. 51 Following tissue damage, ferritin is released into the bloodstream; circulating ferritin loses part of the inner iron content, producing high levels of free iron. 52, 53 Another possible link between COVID-19 and mucormycosis is the development of ketoacidosis. Ketonemia and ketoacidosis have been observed in patients with COVID-19, even in the absence of diabetes mellitus. 54 Apart from raising free iron levels, acidosis impairs phagocytic activity predisposing to mucormycosis. 44 The use of glucocorticoids is a known risk factor for the development of mucormycosis. 41 9 The likely association between COVID-19 and mucormycosis has been schematically represented in Figure 2 . Another indirect association between the concomitant surge in COVID-19 and mucormycosis is the dissemination of fungal spores via water used in oxygen humidifiers. Indeed, hospital water is a potential reservoir for fungi including Mucorales. 55 Transmission of mucormycosis via water in oxygen humidifiers could be a potential reason for the disproportionate increase in the number of CAM cases in a developing country like India. We found that in nearly one-third of the cases of CAM, there was a prior history of COVID-19. This necessitates continued vigilance antifungal therapy was associated with improved clinical outcomes. None. None to declare. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report Acute invasive rhinoorbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome Rhino-orbital mucormycosis associated with COVID-19. Cureus Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study Mucor in a viral land: a tale of two pathogens When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now Sino-orbital mucormycosis in a COVID-19 patient: a case report Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report A case series of invasive mucormycosis in patients with COVID-19 infection Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum Spike in rhino-orbitalcerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. Front Med (Lausanne) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration 19 Treatment Guidelines A case report of COVID-19 associated pulmonary mucormycosis. Arch Clin Cases Rhinocerebral Mucormycosis and COVID-19 Pneumonia Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically Ill COVID-19 patient with underlying hematological malignancy A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus A fatal case of Rhizopus azygosporus pneumonia following COVID-19 Pulmonary aspergillosis and mucormycosis in a patient with COVID-19 Vineeth VK COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? Title of the article: paranasal mucormycosis in COVID-19 patient Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipientcase report and review of literature Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19 Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature COVID-19 and orbital mucormycosis Painful palatal lesion in a patient with COVID-19. Oral Surg Oral Med Oral Pathol Oral Radiol COVID-19-Associated Mold Infection in Critically Ill Patients SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg Rhinocerebral mucormycosis: a retrospective study Global epidemiology of mucormycosis IDF Diabetes ATLAS Ninth Edition Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes Pathogenesis of mucormycosis Pulmonary defense mechanisms against opportunistic fungal pathogens Monocytemediated damage to Rhizopus oryzae hyphae in vitro Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas COVID-19 and the endocrine system: exploring the unexplored COVID-19 and diabetes mellitus: an unholy interaction of two pandemics Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus SARS-CoV-2 infection: the role of cytokines in COVID-19 disease Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators COVID -19 infection may cause ketosis and ketoacidosis Healthcare-associated mucormycosis Disease entities in mucormycosis Novel perspectives on mucormycosis: pathophysiology, presentation, and management Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence: survival outcomes in invasive fungal sinusitis The microscope drape method to reduce aerosolisation during endoscopic sinus and skull base surgery in the COVID era. How i do it COVID-19-associated mucormycosis: An updated systematic review of literature